Ibandronate Sodium 150 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 150 mg

Reference Brands: Boniva (USA), Iasibon (EU)

Category: Osteoporosis

Ibandronate is a bisphosphonate used to treat and prevent osteoporosis, especially in postmenopausal women. It works by reducing bone breakdown and increasing bone density to lower fracture risk. It is typically prescribed either as a monthly oral tablet or quarterly intravenous dose. It must be taken with specific precautions to prevent stomach or esophageal irritation.

Product Description:

Ibandronate is a nitrogen-containing bisphosphonate. Bisphosphonates bind avidly to the mineral surface of bone and are taken up by osteoclasts as they resorb it; inside the cell the drug blocks farnesyl pyrophosphate synthase, disabling the enzyme machinery the osteoclast needs to attach to bone and function. The cell effectively retires, resorption falls, and bone density rises because formation continues unopposed.

It is used to treat and prevent postmenopausal osteoporosis, as a monthly tablet or a three-monthly intravenous injection. Oral bisphosphonate absorption is famously poor — well under one per cent — and food, calcium, coffee and juice abolish it entirely, which is why the tablet must be taken on waking with plain water, upright, with nothing else for at least an hour. That upright hour also prevents oesophageal irritation and ulceration. Osteonecrosis of the jaw and atypical femoral fracture are rare but recognised with long-term use.

Sourcing notes. Off patent and multi-source in both presentations. The monthly tablet and quarterly injection serve the same indication with very different adherence profiles — the injection suits patients who cannot manage the dosing ritual or who have oesophageal disease. Specify which. Room temperature.